Canaccord notes that NASH stocks continue to get pummeled coming out of this year’s EASL conference and ADA annual meeting despite positive data and general news. There are several general factors that are coming into play, but the main instigator is Eli Lilly’s (LLY) Phase II data from retatrutide, a GLP-1/GIP/glucagon receptor agonist. Drugs that target GLP-1, GLP-1/GIP and GLP-1/GIP/glucagon are referred to collectively as incretins. The firm believes incretin drugs approved and in development should be viewed as complementary to NASH therapeutics in development and not as competitors. In addition, lean NASH patients could be another differentiating group for drugs with an anti-fibrotic effect. Canaccord would be strong buyers of Madrigal Pharmaceuticals (MDGL) and Akero Therapeutics (AKRO) given the recent selloff. The firm has Buy rating on both stocks.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AKRO:
- Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology
- Akero Therapeutics presents analyses of Phase 2b HARMONY study
- Akero Therapeutics participates in a conference call with JPMorgan
- Apple downgraded, Oracle upgraded: Wall Street’s top analyst calls
- 89bio initiated with an Outperform at Evercore ISI